MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

Malignant Testicular Germ Cell Tumor Clinical Trial

Official title: Phase II Trial of Serum Micro RNA-371 in Detecting Active Germ Cell Tumors in Patients With Suspected Regional Disease - (MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial)

Status Recruiting

Clinical Trial Summary

This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.

Clinical Trial Description

PRIMARY OBJECTIVE:

I. To measure the accuracy of the blood-based biomarker miRNA-371 to predict pre-operatively the presence of active germ cell malignancy.

OUTLINE: This is an observational study.

Patients undergo blood sample collection during screening and throughout the study. Patients whose screening blood samples show elevated miRNA-371 proceed to standard RPLND surgery. Patients whose screening blood samples show normal levels of miRNA-371 undergo standard surveillance followed by standard RPLND surgery at the time of elevated miRNA-371 levels. Patients may also have their medical records reviewed. ;

Related Conditions & MeSH terms

• Malignant Testicular Germ Cell Tumor
• Neoplasm Metastasis
• Neoplasms, Germ Cell and Embryonal
• Testicular Neoplasms

• NCT number: NCT06060873
• Study type: Observational
• Source: University of Southern California
• Contact: Ileana Aldana
• Phone: 323-865-0702
• Email: Ileana.Aldana@med.usc.edu
• Status: Recruiting
• Start date: June 8, 2023
• Completion date: December 8, 2028